Heron Therapeutics | HRTX - Des Atouts

Prix De L'Action
0.85
Variation Quotidienne
0.03 4.10%
Mensuellement
-12.06%
Annuel
-55.34%
Q2 Prévisions
0.83




Des Atouts Changement Date
ALKERMES USD 2.49B 157.48M 2025-12
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Amarin USD 670.78M 10.96M 2025-12
ANI Pharmaceuticals USD 1.44B 32.22M 2025-12
Anika Therapeutics USD 190.27M 833K 2025-12
Arrowhead Research USD 1.6B 218.89M 2025-12
Eisai JPY 1.49T 48.22B 2025-12
Emergent BioSolutions USD 1.82B 69.9M 2023-12
Esperion Therapeutics USD 465.89M 101.87M 2025-12
GlaxoSmithKline GBP 61.12B 221M 2025-12
Heron Therapeutics USD 255.88M 6.93M 2025-12
Insmed USD 2.26B 96.18M 2025-12
Ligand Pharmaceuticals USD 1.56B 83.86M 2025-12
Merck USD 129.55B 12.02B 2025-09
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Omeros USD 200.57M 34.59M 2025-06
Pacira USD 1.26B 32.66M 2025-12
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Roche Holding CHF 100.7B 5.94B 2025-12
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Surmodics USD 169.82M 8.74M 2025-06
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
Veracyte USD 1.41B 38.23M 2025-12
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12